Brokerages Set The Medicines Co. (MDCO) PT at $48.40
The Medicines Co. (NASDAQ:MDCO) has earned an average rating of “Buy” from the twelve analysts that are covering the firm. Three research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $48.40.
Several analysts have commented on MDCO shares. JPMorgan Chase & Co. reissued a “buy” rating on shares of The Medicines in a research report on Thursday, October 6th. RBC Capital Markets increased their price target on shares of The Medicines from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, November 16th. Jefferies Group reissued a “buy” rating and set a $43.00 price target on shares of The Medicines in a research report on Wednesday, November 16th. Guggenheim reissued a “buy” rating and set a $55.00 price target on shares of The Medicines in a research report on Monday, August 15th. Finally, Cowen and Company reissued a “buy” rating and set a $45.00 price target on shares of The Medicines in a research report on Friday, August 5th.
In related news, CEO Clive Meanwell sold 1,377 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $40.00, for a total value of $55,080.00. Following the transaction, the chief executive officer now owns 339,168 shares in the company, valued at approximately $13,566,720. The sale was disclosed in a filing with the SEC, which is available through this link. 7.90% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Capstone Asset Management Co. increased its position in shares of The Medicines by 4.5% in the second quarter. Capstone Asset Management Co. now owns 21,699 shares of the company’s stock valued at $730,000 after buying an additional 940 shares during the period. Macquarie Group Ltd. raised its stake in The Medicines by 27.6% in the second quarter. Macquarie Group Ltd. now owns 532,035 shares of the company’s stock valued at $17,892,000 after buying an additional 115,218 shares in the last quarter. Vanguard Group Inc. raised its stake in The Medicines by 3.9% in the second quarter. Vanguard Group Inc. now owns 5,423,391 shares of the company’s stock valued at $182,388,000 after buying an additional 202,392 shares in the last quarter. Ameriprise Financial Inc. raised its stake in The Medicines by 4.5% in the second quarter. Ameriprise Financial Inc. now owns 339,057 shares of the company’s stock valued at $11,402,000 after buying an additional 14,662 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in The Medicines by 0.3% in the second quarter. Louisiana State Employees Retirement System now owns 30,800 shares of the company’s stock valued at $1,036,000 after buying an additional 100 shares in the last quarter.
The Medicines (NASDAQ:MDCO) opened at 37.23 on Wednesday. The company has a 50 day moving average of $35.53 and a 200-day moving average of $36.65. The stock’s market cap is $2.61 billion. The Medicines has a 12-month low of $27.50 and a 12-month high of $43.00.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings data on Wednesday, October 26th. The company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.30) by $0.66. The Medicines had a negative net margin of 96.44% and a negative return on equity of 35.07%. The company earned $37.60 million during the quarter, compared to analyst estimates of $37.26 million. During the same period in the prior year, the firm earned ($0.82) earnings per share. The firm’s revenue for the quarter was down 34.3% compared to the same quarter last year. Equities analysts forecast that The Medicines will post ($1.41) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/28/brokerages-set-the-medicines-co-mdco-pt-at-48-40.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).
Receive News & Stock Ratings for The Medicines Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Co. and related stocks with our FREE daily email newsletter.